GGrantIndex
← Leaderboards

Larry W Kwak

Clinical Sciences

$10,852,773
Attributed
$12,264,396
Total exposure
11
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.7M · FY200725
$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$27,216,664 · 13

By mechanism

P50$22,580,526 · 8
R01$1,985,435 · 1
P30$1,839,738 · 2
R21$810,965 · 2

Top collaborators

Most similar at Clinical Sciences

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Trials

Research focus

Clinical TrialsResearch PersonnelLymphomaInnovationMultiple MyelomaClinical ResearchCitiesFundingTranslational ResearchBaseProgramsT-LymphocyteImmunoglobulin IdiotypesTranslatingGrantTumor AntigensNovel TherapeuticsInstitutionResourcesLaboratoriesTrainingMeetingsPilot ProjectsNeoplasm /Cancer Vaccine

Grant awards (65)

Developmental Funds$207,242
P30 · FY2025 · CA · contact PI
BAFF-R CAR T cell therapy for ALL$643,742
R01 · FY2024 · CA · contact PI
Developmental Funds$204,199
P30 · FY2024 · CA · contact PI
BAFF-R CAR T cell therapy for ALL$664,070
R01 · FY2023 · CA · contact PI
Developmental Funds$159,194
P30 · FY2023 · CA · contact PI
City of Hope Lymphoma SPORE$2,307,384
P50 · FY2022 · CA
BAFF-R CAR T cell therapy for ALL$677,623
R01 · FY2022 · CA · contact PI
GMP Manufacturing$388,562
P50 · FY2022 · CA · contact PI
Developmental Research Program$123,114
P50 · FY2022 · CA · contact PI
Core A: Administrative Core$110,983
P50 · FY2022 · CA · contact PI
City of Hope Lymphoma SPORE$2,324,819
P50 · FY2021 · CA
Clinical Protocol and Data Management$338,773
P30 · FY2021 · CA · contact PI
GMP Manufacturing$233,192
P50 · FY2021 · CA · contact PI
Developmental Research Program$80,443
P50 · FY2021 · CA · contact PI
Core A: Administrative Core$60,927
P50 · FY2021 · CA · contact PI
City of Hope Lymphoma SPORE$2,359,066
P50 · FY2020 · CA
Clinical Protocol and Data Management$345,915
P30 · FY2020 · CA · contact PI
GMP Manufacturing$256,902
P50 · FY2020 · CA · contact PI
Translation development of a novel therapeutic antibody against drug-resistant B-cell malignancies$225,765
R21 · FY2020 · CA · contact PI
Transfer of COVID-19 Immunity Between Allogeneic Transplant Donors and Recipients$176,000
P50 · FY2020 · CA
Transfer of COVID-19 Immunity Between$176,000
P50 · FY2020 · CA
Developmental Research Program$117,509
P50 · FY2020 · CA · contact PI
City of Hope Lymphoma SPORE$2,324,999
P50 · FY2019 · CA
GMP Manufacturing$353,962
P50 · FY2019 · CA · contact PI
Clinical Protocol and Data Management$329,539
P30 · FY2019 · CA · contact PI
Developmental Research Program$68,651
P50 · FY2019 · CA · contact PI
City of Hope Lymphoma SPORE$2,500,000
P50 · FY2018 · CA
GMP Manufacturing$313,709
P50 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$252,793
P30 · FY2018 · CA · contact PI
Developmental Research Program$84,460
P50 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$2,083
P30 · FY2018 · CA · contact PI
City of Hope Lymphoma SPORE$300,000
P50 · FY2017 · CA
City of Hope Lymphoma SPORE$2,185,000
P50 · FY2015 · CA
P1 - COMBINATION ACTIVATED T-CELL AND VACCINE THERAPY IN MYELOMA$947,589
P50 · FY2014 · CA · contact PI
CAREER DEVELOPMENT PROGRAM$90,256
P50 · FY2014 · CA · contact PI
P1 - COMBINATION ACTIVATED T-CELL AND VACCINE THERAPY IN MYELOMA$961,866
P50 · FY2013 · CA · contact PI
CAREER DEVELOPMENT PROGRAM$101,819
P50 · FY2013 · CA · contact PI
P1 - COMBINATION ACTIVATED T-CELL AND VACCINE THERAPY IN MYELOMA$959,257
P50 · FY2012 · CA · contact PI
CAREER DEVELOPMENT PROGRAM$103,285
P50 · FY2012 · CA · contact PI
P1 - COMBINATION ACTIVATED T-CELL AND VACCINE THERAPY IN MYELOMA$914,897
P50 · FY2011 · CA · contact PI
UT M.D. Anderson Cancer Center Lymphoma SPORE$475,000
P50 · FY2011 · CA · contact PI
CAREER DEVELOPMENT PROGRAM$98,050
P50 · FY2011 · CA · contact PI
P1 - COMBINATION ACTIVATED T-CELL AND VACCINE THERAPY IN MYELOMA$980,225
P50 · FY2010 · CA · contact PI
CAREER DEVELOPMENT PROGRAM$102,600
P50 · FY2010 · CA · contact PI
Immunization of Stem Cell Transplant Donors to Enhance Graft-versus-Tumor Effect$292,600
R21 · FY2008 · CA · contact PI
Immunization of Stem Cell Transplant Donors to Enhance Graft-versus-Tumor Effect$292,600
R21 · FY2007 · CA · contact PI
Cancer Vaccines for Lymphomas$0
Z01 · FY2004 · SC
Immunization of Stem Cell Transplant Donors with Myeloma$0
Z01 · FY2004 · SC
Genetic Cancer Vaccines$0
Z01 · FY2004 · SC
Cellular and Humoral Immunity Against Myeloma Idiotype$0
Z01 · FY2004 · SC
Cancer Vaccines for Lymphomas$0
Z01 · FY2003 · SC
Immunization of Stem Cell Transplant Donors with Myeloma$0
Z01 · FY2003 · SC
Genetic Cancer Vaccines$0
Z01 · FY2003 · SC
Evaluation of Cellular /Humoral Immunity Against Myeloma$0
Z01 · FY2003 · SC
Cancer Vaccines for Lymphomas$0
Z01 · FY2002 · SC
Immunization of Stem Cell Transplant Donors with Myeloma$0
Z01 · FY2002 · SC
Genetic Cancer Vaccines$0
Z01 · FY2002 · SC
Evaluation of Cellular and Humoral Immunity Against Myel$0
Z01 · FY2002 · SC
Cancer Vaccines for Lymphomas$0
Z01 · FY2001 · SC
Genetic Cancer Vaccines$0
Z01 · FY2001 · SC
Evaluation of Cellular and Humoral Immunity Against Myel$0
Z01 · FY2001 · SC
Evaluation of Cellular and Humoral Immunity Against Myeloma Idiotype$0
Z01 · FY2000 · SC
Genetic Cancer Vaccines$0
Z01 · FY2000 · SC
Cancer Vaccines for Lymphomas$0
Z01 · FY2000 · SC
IMMUNIZATION OF STEM CELL TRANSPLANT DONORS WITH MYELOMA$0
Z01 · FY2000 · SC